PERSPECTIVES: Stroke survivors' views on the design of an early-phase cell therapy trial for patients with chronic ischaemic stroke.
Anjali NagpalSusan HillierAustin G MiltonMonica A Hamilton-BruceSimon A KoblarPublished in: Health expectations : an international journal of public participation in health care and health policy (2019)
Participants conveyed that the most relevant outcomes to them were regaining participation, decreased dependence on caregivers and improvement in cognition, memory, mood, pain and fatigue. The perception of risk vs. benefit was likely influenced by the time elapsed since stroke, with participants being more willing to accept a higher level of risk early in the post-stroke disease course. They believed that all stroke survivors should be given an opportunity to participate in research, irrespective of their cognitive capacity. A relatively small sample population of 12 stroke survivors was studied as thematic saturation was achieved. PERSPECTIVES study applied principles of PPIR to early-phase cell research. Incorporation of outcomes relevant to patients' need within the study design is critical to generate data that will enable personalized application of regenerative medicine in stroke.
Keyphrases
- atrial fibrillation
- cell therapy
- stem cells
- end stage renal disease
- clinical trial
- chronic kidney disease
- cerebral ischemia
- physical activity
- palliative care
- randomized controlled trial
- newly diagnosed
- mesenchymal stem cells
- chronic pain
- study protocol
- multiple sclerosis
- depressive symptoms
- pain management
- bone marrow
- open label
- neuropathic pain
- patient reported outcomes
- data analysis
- double blind